跳至主要内容
临床试验/CTRI/2020/07/026347
CTRI/2020/07/026347尚未招募未知

To compare the outcomes of 0.1mg and 0.25mg of intravitreal Ranibizumab in the management of Aggressive Posterior Retinopathy of Prematurity.

Dr Rajendra Prasad Centre for Ophthalmic Science All India Institute of Medical Science New Delhi0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Pre-term babies (Gestational Age < 34 weeks)
  • 2. Birth Weight <2000gm
  • 3. Zone I â?? Zone II Posterior APROP
  • 4. Bilateral symmetrical disease

排除标准

  • 1. Advanced stage disease (stage 4/ 5 ROP)
  • 2. Zone II anterior and Zone III disease (non-APROP)
  • 3. Any previous intervention done (Laser/ Anti-VEGF)
  • 4. Any other ocular abnormality

研究者

发起方
Dr Rajendra Prasad Centre for Ophthalmic Science All India Institute of Medical Science New Delhi

相似试验